Nancy Gudgeon

Nancy Gudgeon

Auto-generated profile, based on publicly available information

Nancy Gudgeon

Department of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Science Signaling
Verified
Journal Article
Closed access
EBEmma L. Bishop
Emma L. Bishop
NGNancy Gudgeon
Nancy Gudgeon
TFTaylor Fulton-Ward
Taylor Fulton-Ward
VSVictoria Stavrou
Victoria Stavrou
JRJennie Roberts
Jennie Roberts
SDSarah Dimeloe
Sarah Dimeloe
Upon activation, T cells undergo metabolic reprogramming to meet the bioenergetic demands of clonal expansion and effector function. Because dysregulated T cell cytokine production and metabolic phenotypes coexist in chronic inflammatory disease, including rheumatoid arthritis (RA), we investigated whether inflammatory cytokines released by differentiating T cells amplified their metabolic changes. We found that tumor necrosis factor–α (TNF-α) released by human naïve CD4 + T cells upon activation stimulated the expression of a metabolic transcriptome and increased glycolysis, amino acid uptake, mitochondrial oxidation of glutamine, and mitochondrial biogenesis. The effects of TNF-α were mediated by activation of Akt-mTOR signaling by the kinase ITK and did not require the NF-κB pathway. TNF-α stimulated the differentiation of naïve cells into proinflammatory T helper 1 (T H 1) and T H 17 cells, but not that of regulatory T cells. CD4 + T cells from patients with RA showed increased TNF-α production and consequent Akt phosphorylation upon activation. These cells also exhibited increased mitochondrial mass, particularly within proinflammatory T cell subsets implicated in disease. Together, these findings suggest that T cell–derived TNF-α drives their metabolic reprogramming by promoting signaling through ITK, Akt, and mTOR, which is dysregulated in autoinflammatory disease.

11 October 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
NGNancy Gudgeon
Nancy Gudgeon
HGHannah Giles
Hannah Giles
EBEmma L. Bishop
Emma L. Bishop
TFTaylor Fulton-Ward
Taylor Fulton-Ward
CECristina Escribano-Gonzalez
Cristina Escribano-Gonzalez
SDSarah Dimeloe
Sarah Dimeloe
T cells demonstrate impaired function in multiple myeloma (MM) but suppressive mechanisms in the bone marrow microenvironment remain poorly defined. We observe that bone marrow CD8+ T-cell function is decreased in MM compared with controls, and is also consistently lower within bone marrow samples than in matched peripheral blood samples. These changes are accompanied by decreased mitochondrial mass and markedly elevated long-chain fatty acid uptake. In vitro modeling confirmed that uptake of bone marrow lipids suppresses CD8+ T function, which is impaired in autologous bone marrow plasma but rescued by lipid removal. Analysis of single-cell RNA-sequencing data identified expression of fatty acid transport protein 1 (FATP1) in bone marrow CD8+ T cells in MM, and FATP1 blockade also rescued CD8+ T-cell function, thereby identifying this as a novel target to augment T-cell activity in MM. Finally, analysis of samples from cohorts of patients who had received treatment identified that CD8+ T-cell metabolic dysfunction resolves in patients with MM who are responsive to treatment but not in patients with relapsed MM, and is associated with substantial T-cell functional restoration.

20 June 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMegan R. Teh
Megan R. Teh
NGNancy Gudgeon
Nancy Gudgeon
JFJoe N. Frost
Joe N. Frost
LSLinda V. Sinclair
Linda V. Sinclair
ASAlastair L. Smith
Alastair L. Smith
ADAlexander Drakesmith
Alexander Drakesmith
Iron is an irreplaceable co-factor for metabolism. Iron deficiency affects >1 billion people and decreased iron availability impairs immunity. Nevertheless, how iron deprivation impacts immune cell function remains poorly characterised. We interrogate how physiologically low iron availability affects CD8+ T cell metabolism and function, using multi-omic and metabolic labelling approaches. Iron limitation does not substantially alter initial post-activation increases in cell size and CD25 upregulation. However, low iron profoundly stalls proliferation (without influencing cell viability), alters histone methylation status, gene expression, and disrupts mitochondrial membrane potential. Glucose and glutamine metabolism in the TCA cycle is limited and partially reverses to a reductive trajectory. Previous studies identified mitochondria-derived aspartate as crucial for proliferation of transformed cells. Despite aberrant TCA cycling, aspartate is increased in stalled iron deficient CD8+ T cells but is not utilised for nucleotide synthesis, likely due to trapping within depolarised mitochondria. Exogenous aspartate markedly rescues expansion and some functions of severely iron-deficient CD8+ T cells. Overall, iron scarcity creates a mitochondrial-located metabolic bottleneck, which is bypassed by supplying inhibited biochemical processes with aspartate. These findings reveal molecular consequences of iron deficiency for CD8+ T cell function, providing mechanistic insight into the basis for immune impairment during iron deficiency.

2 December 2025 in Blood Advances
Verified
Journal Article
Open access
TFTaylor Fulton-Ward
Taylor Fulton-Ward
NGNancy Gudgeon
Nancy Gudgeon
ITIsaac Thirlwell
Isaac Thirlwell
EBEmma L. Bishop
Emma L. Bishop
BMBryan Marzullo
Bryan Marzullo
SDSarah Dimeloe
Sarah Dimeloe
Novel therapies for multiple myeloma (MM) aim to engage antitumor functions of T cells. However, evidence indicates these functions are limited within the bone marrow (BM) environment. This is relatively hypoxic in health, and studies indicate widespread hypoxia in MM. In this study, CD8+ T-cell responses to stimulation were assessed under hypoxia, which identified that activation, proliferation, and interferon-gamma (IFN-γ) secretion were profoundly suppressed, while cytotoxicity and tumor necrosis factor-α (TNF-α) expression were unaffected. These changes occurred alongside decreased mechanistic target of rapamycin (mTOR) activity and expression of c-Myc, which drives T-cell metabolic reprogramming upon stimulation. Consistently, hypoxic CD8+ T cells demonstrated decreased activation-induced glycolysis and mitochondrial glutamine oxidation. Mechanistically, this was linked to elevated BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) expression under hypoxia, and reciprocally decreased abundance of its interaction partner, Ras homolog enriched in brain (Rheb), an important mTOR activator. Assessment of BCMA×CD3 bispecific antibody activity confirmed impaired capacity to elicit CD8+ T-cell activation, IFN-γ expression, proliferation, and altered memory differentiation under hypoxia, although initial target cell killing was unaffected. Finally, assessment of BM CD8+ T cells from patients with MM identified decreased proliferation, c-Myc, and Rheb expression compared with peripheral blood cells, alongside elevated BNIP3, confirming mechanistic features of hypoxic exposure in this environment. Taken together, the findings indicate potential for BM hypoxia to influence efficacy of T cell–directed therapies for MM.

4 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVictoria Stavrou
Victoria Stavrou
MAMyah Ali
Myah Ali
NGNancy Gudgeon
Nancy Gudgeon
EBEmma L. Bishop
Emma L. Bishop
TFTaylor Fulton-Ward
Taylor Fulton-Ward
SDSarah Dimeloe
Sarah Dimeloe
T cell metabolism increases upon activation, underpinning immune effector functions. Nicotinamide adenine dinucleotide (NAD/H) is an essential redox cofactor for glycolysis and mitochondrial substrate oxidation. It’s phosphorylation to NADP/H regulates reactive oxygen species (ROS) abundance. NAD/H levels increase upon T cell activation, but synthesis pathways and implications are not fully characterised. Here, we interrogate the role of the NAD/H-synthesis enzyme nicotinamide riboside kinase 1 (NRK1), the expression of which increases upon stimulation of both human and murine CD4 + T cells. Functionally, NRK1 activity restrains activation and cytokine production of CD4 + T cells while promoting survival. These activities are linked to increased NRK1 expression in the cytoplasm, where it locally raises NAD/H levels. This supports glycolysis, but more profoundly impacts cytoplasmic NADP/H generation, thereby controlling ROS abundance and nuclear NFAT translocation. During fungal and viral infection, T-cell-intrinsic NRK1 maintains effector CD4 + T cell abundance within affected tissues and draining lymph nodes, supporting infection control. Taken together, these data confirm that subcellular regulation of immune cell metabolism determines immune responses at the level of whole organism.

13 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAlastair Copland
Alastair Copland
GMGillian M. Mackie
Gillian M. Mackie
LSLisa Scarfe
Lisa Scarfe
DLDavid A.J. Lecky
David A.J. Lecky
NGNancy Gudgeon
Nancy Gudgeon
KMKendle M. Maslowski
Kendle M. Maslowski
Summary: Bacterial cancer therapy (BCT) is a promising therapeutic for solid tumours. Salmonella enterica Typhimurium (STm) is well-studied amongst bacterial vectors due to advantages in genetic modification and metabolic adaptation. A longstanding paradox is the redundancy of T cells for treatment efficacy; instead, STm BCT depends on innate phagocytes for tumour control. Here, we used distal T cell receptor (TCR) reporter mice ( Nr4a3-Tocky-Ifng-YFP ) and a colorectal cancer (CRC) model to interrogate T cell activity during BCT with attenuated STm. We found that colonic TILs exhibited a variety of activation defects, including IFN-γ production decoupled from TCR signalling, decreased polyfunctionality and reduced T CM formation. Modelling of T-cell–tumour interactions with a tumour organoid platform revealed an intact TCR signalosome, but paralysed metabolic reprogramming due to inhibition of the master metabolic controller, c-Myc. Restoration of c-Myc by deletion of the bacterial asparaginase ansB reinvigorated T cell activation, but at the cost of decreased metabolic control of the tumour by STm. This work shows for the first time that T cells are metabolically defective during BCT, but also that this same phenomenon is inexorably tied to intrinsic tumour suppression by the bacterial vector.